SWOG clinical trial number
CTSU/A031704

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Open
Phase
Abbreviated Title
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Activated
05/09/2019
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Ipilimumab Cabozantinib Nivolumab

Other Clinical Trials

S2312
SWOG Clinical Trial Number

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature

Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
4% Accrual
Accrual
4%
Open
Phase
S2210
SWOG Clinical Trial Number

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
9% Accrual
Accrual
9%
Open
Phase
S2200
SWOG Clinical Trial Number

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2

Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
16% Accrual
Accrual
16%
Open
Phase